What are the best treatments for Pigmented villonodular synovitis?

The primary treatment for Pigmented villonodular synovitis (now more commonly referred to as tenosynovial giant cell tumor, or TGCT) is surgical excision, typically performed via arthroscopy or open synovectomy. In cases where the disease is diffuse, recurrent, or surgically inaccessible, systemic therapy with CSF1R inhibitors may be utilized to manage symptoms and tumor progression.

What are the current first-line treatments for Pigmented villonodular synovitis?

For most patients, the gold standard for managing Pigmented villonodular synovitis is surgical removal of the affected synovial tissue. For localized disease, a complete resection often leads to excellent long-term outcomes. However, when the condition presents in a diffuse form, it involves the entire joint lining, making complete surgical removal more challenging and increasing the risk of recurrence. Surgeons must weigh the risks of joint morbidity against the goal of achieving clear margins to minimize the chance of the condition returning.

What medications are used to treat Pigmented villonodular synovitis?

While surgery remains the mainstay, pharmacological interventions have evolved for complex cases. The FDA-approved medication pexidartinib (Turalio) is a colony-stimulating factor 1 receptor (CSF1R) inhibitor used for symptomatic Pigmented villonodular synovitis that is not amenable to improvement with surgery. Other agents, such as emactuzumab or cabiralizumab, have been investigated in clinical trials. These systemic treatments target the underlying biological pathway that drives the overgrowth of synovial cells, helping to reduce tumor volume and alleviate pain in patients who have exhausted surgical options.

How is a multidisciplinary care team structured?

Because Pigmented villonodular synovitis can significantly impact joint function and mobility, a multidisciplinary approach is essential for optimal outcomes. A typical care team should include:

• Orthopedic Surgeons: Specifically those with sub-specialization in orthopedic oncology or sports medicine.


• Medical Oncologists: To manage systemic therapies and monitor for side effects of CSF1R inhibitors.


• Physical Therapists: To restore range of motion and muscle strength post-surgery.


• Radiologists: With expertise in musculoskeletal imaging to track tumor regression or recurrence.


• Clinical Geneticists: To provide counseling, as the condition involves specific chromosomal translocations (e.g., COL6A3-CSF1 fusion).

What non-pharmacological interventions are recommended?

Non-pharmacological strategies are vital for rehabilitation and quality of life. Following surgical intervention for Pigmented villonodular synovitis, physical therapy is critical to prevent joint stiffness and atrophy of the surrounding musculature. Occupational therapy may be required if the disease affects joints in the hands or wrists, ensuring that patients can maintain their daily activities. With 31 members currently in the DiseaseMaps community, many patients emphasize that consistent, guided rehabilitation is just as important as the initial surgical procedure in achieving a high level of functional recovery.

How does treatment effectiveness vary between patients?

Treatment success for Pigmented villonodular synovitis is highly variable and depends on whether the disease is localized or diffuse. Localized disease often responds well to a single surgical intervention. In contrast, diffuse Pigmented villonodular synovitis has a recurrence rate that can exceed 40–50% in some clinical studies, necessitating long-term surveillance through MRI. Every patient's experience is unique, and treatment plans must be personalized based on the specific joint involved, the extent of the synovial involvement, and the patient's individual functional goals.

Next steps

• Consult with an orthopedic oncologist to discuss whether your case is localized or diffuse.


• Request a baseline MRI to monitor for potential recurrence, even if you are currently asymptomatic.


• Connect with the 31 other members of the DiseaseMaps.org community to share experiences on recovery and management.


• Discuss the potential benefits and side effects of systemic therapies with a specialist if you have experienced multiple recurrences.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult with your healthcare provider to develop a treatment plan tailored to your specific clinical needs.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Tenosynovial Giant Cell Tumor.


• Orphanet: Pigmented Villonodular Synovitis (ORPHA:3198).


• National Cancer Institute (NCI): Targeted Therapy for Tenosynovial Giant Cell Tumor.


• OMIM (Online Mendelian Inheritance in Man): Entry #192600.